Results: Intragastric administration of TFF-secreting L. lactis led to active delivery of TFF at the mucosa of the colon and, in contrast to administration of purified TFF, proved to be very effective in prevention and healing of acute DSS-induced colitis.
Results: Intragastric administration of OVA-secreting L lactis led to active delivery of OVA at the mucosa and suppression of local and systemic OVA-specific T-cell responses in DO11.10 mice.
The active delivery of probiotic cells in microencapsulated form has received reasonable attention during the last 10 years, since it can reduce losses of sensitive bacteria induced by detrimental external factors during storage and digestion [1].
Active delivery of recombinant autoantigens or allergens at the intestinal mucosa by genetically modified Lactococcus lactis (L lactis) provides a novel therapeutic approach for inducing tolerance.
This study opens a new perspective of active delivery of antitumor drug against breast cancer and its lymph node metastases with inspiring therapeutic effect and little side effects.
Results: Oral administration of LcrV-secreting L lactis led to active delivery of LcrV and induction of IL-10 (via a Toll-like receptor 2 dependent pathway) in the colon and prevented TNBS-induced colitis, in contrast to the L lactis control not producing LcrV.
Two possibilities have been proposed for how this might occur: either the neurons that encode the tone remain active until delivery of the air puff, or different groups of neurons are successively activated in a relay that spans the interval between the tone and the air puff.
In this study, laser-engineered dissolving microneedle (DMN) arrays fabricated from aqueous blends of 15% w/w poly methylvinylether-co-maleic anhydride) were used for the first time in active transdermal delivery of the LMWH nadropoly methylvinylether-co-maleic
To our knowledge, we report the first successful demonstration of the active delivery, using macrophages, of nanoparticles to brain metastases and it paves the way for testing this method to deliver other nanovectors including nanorods, hollow nanospheres in the sub-100 and sub-50 nm range as well as nanoformulated therapeutics.
This would provide the proof of concept of active delivery vehicles able to guide their movement towards diseased cells.
